Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
EDRN is a leader in defining and using criteria for the validation of biomarkers—an essential condition for scientific progress. While myriad proteins and genes have been linked with a variety of cancers, acceptable biomarkers must be: reliable and repeatable in testing; highly sensitive and specific; quantitative; readily obtained by non-invasive methods; part of the causal pathway for disease; capable of being modulated by the che- mopreventive agent; and have high predictive value for clinical disease. EDRN is helping translate the discovery and validation of biomarkers to clinical use and we are delighted to be working toward that end. . | Commission on Cancer 2009 REVISED EDITION H Commission on Cancer A multidisciplinary program of the American College of Surgeons 2003 2006 2009 American College of Surgeons Chicago IL All rights reserved The American College of Surgeons does not warrant or make any guarantees or assurances related to outcomes of treatment provided by institutions that have cancer programs approved by the Commission on Cancer. The examples used herein are to be used as guidelines and are not wholly inclusive of all options. Dedication This publication is dedicated to individual cancer program team members. Your participation in the Commission on Cancer Approvals Program exemplifies a steadfast commitment to providing the best care possible for your cancer patients and members of your community. Your leadership and expertise contribute to the entire scope organization and performance of the cancer program. Your vision is a catalyst for continued growth and improvement to ensure the delivery of high-quality cancer care. .
